Chen Lijin, Li Yingying, Zhao Hong, Huang Jinyuan, Yan Huimeng, Lin Xiaoyan, Zhao Bin
Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, China.
Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian 362000, China.
Genes Dis. 2024 Nov 8;12(4):101450. doi: 10.1016/j.gendis.2024.101450. eCollection 2025 Jul.
The mesenchymal-epithelial transition factor () proto-oncogene plays important roles during tumor development. Recently, evidence has revealed signaling may impact tumor immunogenicity and regulate the immune response. Here we conducted a comprehensive bioinformatic and clinical analysis to explore the characteristics of mutation and its association with the outcomes in pan-cancer immunotherapy. In 4149 patients with 12 tumor types treated with immune checkpoint inhibitors, mutation indicated favorable overall survival (hazard ratio = 0.61; 95% CI, 0.50-0.74; < 0.001), progression-free survival (hazard ratio = 0.74; 95% CI, 0.60-0.92; = 0.01), and objective response rate (40.3% . 28.1%; = 0.003). Moreover, we developed a nomogram to estimate the 12-month and 24-month survival probabilities after the initiation of immunotherapy. Further multi-omics analysis on both intrinsic and extrinsic immune landscapes revealed that mutation enhanced tumor immunogenicity, enriched infiltration of immune cells, and improved immune responses. In summary, mutation improves cancer immunity and is an independent biomarker for favorable outcomes in pan-cancer immunotherapy. These results may influence clinical practices, guide treatment decision-making, and develop immunotherapy for personalized care.
间充质上皮转化因子（）原癌基因在肿瘤发展过程中发挥重要作用。最近，有证据表明信号可能影响肿瘤免疫原性并调节免疫反应。在此，我们进行了全面的生物信息学和临床分析，以探讨在泛癌免疫治疗中突变的特征及其与预后的关联。在4149例接受免疫检查点抑制剂治疗的12种肿瘤类型患者中，突变提示总生存期良好（风险比=0.61；95%可信区间，0.50-0.74；<0.001）、无进展生存期良好（风险比=0.74；95%可信区间，0.60-0.92；=0.01）和客观缓解率良好（40.3%对28.1%；=0.003）。此外，我们制定了一个列线图来估计免疫治疗开始后12个月和24个月的生存概率。对内在和外在免疫格局的进一步多组学分析表明，突变增强了肿瘤免疫原性，丰富了免疫细胞浸润，并改善了免疫反应。总之，突变改善了癌症免疫，是泛癌免疫治疗中预后良好的独立生物标志物。这些结果可能影响临床实践，指导治疗决策，并开发个性化护理的免疫治疗方法。
